Skip Ribbon Commands
Skip to main content

Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy (ADET) of metastatic liver cancer



Tumor response

  • Quality of Life (QoL): 90% Palliative Performance Scale (PPS) at each time point
  • Median time to progression for patients that progressed: 2.5 months (range: 0.8-6)
  • Overall survival (OS): 14 months (range: 1.3-25) during assessed period
  • Median time to follow up: 14 months
  • Complications and side effects: ADETs were performed with no complications

Observed side effects (mild or moderate intensity) were: Pain in 32% of patients, increase of transaminase levels in 20% and fever in 14%, whereas 30% of patients did not complain any adverse event.

​Tumor Response (RECIST 1.1)1 month​3 months​6 months


The therapy of unresectable mCRC with ADET using LifePearl® loaded with irinotecan was effective in tumor response and resulted in mild toxicity, and good QoL. According to the authors these results are very similar to those previously reported with drug eluting beads.